Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you have diverticulitis and are wondering whether semaglutide is safe for you, the short answer is: it depends on your current clinical picture, and a prescriber needs to assess you individually. Semaglutide is not listed as contraindicated in diverticulitis, but its known effects on the gut mean this is a conversation worth having carefully before starting. These are prescription-only medicines — Wegovy (semaglutide injection) and the newer Wegovy tablet — and every patient is assessed by a clinician before a prescription is issued. If you have diverticulitis and are asking whether you can take Wegovy, the fact you're researching this first is exactly the right instinct.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people arrive at this question expecting a flat no. The assumption is understandable: diverticulitis is a bowel condition, semaglutide acts on the gut, therefore the two must be incompatible. The reality is more nuanced than that. Diverticulitis is not listed as an absolute contraindication in semaglutide's UK prescribing information. What the semaglutide Summary of Product Characteristics on the eMC does flag is that caution is warranted in patients with significant gastrointestinal disease, including conditions where delayed gastric emptying or altered bowel function could cause problems.
Diverticulitis exists on a spectrum. Someone who had a single mild episode three years ago and has been symptom-free since is in a very different position from someone managing recurrent flares or a complication such as a fistula or stricture. A prescriber weighs that history, not the diagnosis label alone. The SmPC cautions against use in patients with severe gastrointestinal disease; whether your history meets that threshold is a clinical decision, not one a webpage can make for you.
So the accurate answer to "can you take semaglutide with diverticulitis" is: possibly yes, depending on the severity and current status of your condition, and only after a clinician has reviewed your history. That review is exactly what a structured semaglutide consultation is designed to surface.
Semaglutide works partly by slowing the rate at which the stomach empties and modulating gut motility. For most people, this is what produces feelings of fullness and reduced appetite. For someone whose bowel is already prone to inflammation or narrowing, though, that same slowing effect is worth thinking through carefully.
The side-effect profile of semaglutide is dominated by gastrointestinal symptoms. Nausea is the most frequently reported, especially in the early weeks of treatment; constipation and diarrhoea also appear commonly, and abdominal discomfort is not unusual. During a diverticulitis flare (or even in the period of low-grade sensitivity between flares) these effects could be harder to tolerate and, more practically, harder to interpret. If you develop significant abdominal pain while on semaglutide, your clinical team needs to distinguish between a drug side effect, a diverticulitis flare, and rarer but serious possibilities such as acute pancreatitis. The MHRA's Yellow Card scheme exists precisely so that unexpected reactions in real-world patients can be tracked; your prescriber would also want to know.
This is not a reason to rule semaglutide out. It is a reason to be thoughtful about timing (ideally starting treatment when your diverticulitis is in remission rather than in the middle of a flare) and to keep your prescriber and your GP informed throughout. Disclosing your full bowel history at the outset means your clinician can build that context into their assessment from day one.
Prescribers reviewing a semaglutide consultation for someone with diverticulitis will typically want to understand a few specific things: how recently your last flare occurred, whether you have had any complications (abscess, perforation, fistula, stricture), whether you are currently on any medications for the condition, and whether your bowel function is stable right now. This is not a checklist exercise, it is clinical context that shapes whether semaglutide is appropriate for you, and at what point it would be safest to start.
It is also worth knowing that semaglutide's side-effect burden tends to be front-loaded. The dose-escalation schedule used with Wegovy (starting at 0.25 mg and increasing gradually over several months) is designed in part to give the gut time to adjust, reducing the intensity of early GI symptoms. For someone with diverticulitis, that gradual approach may work in their favour. That said, if you are currently mid-flare and on antibiotics, starting a GLP-1 medicine at the same time is unlikely to be the right moment. A sensible prescriber will usually recommend waiting until you are well and stable.
If you are also taking other medications for related conditions, it is worth reading about which medicines and substances are best avoided when you are using semaglutide, not because interactions with common diverticulitis treatments are well-established, but because a full medication review is part of good prescribing practice. Our clinical team reviews every consultation personally, with that kind of detail in mind.
On the NHS, access to Wegovy is via specialist weight management services and remains restricted under NICE guidance (TA875). For most people with diverticulitis, that complexity does not change the NHS pathway, eligibility is based on BMI and weight-related comorbidities rather than on GI history alone. Waiting lists for specialist services are commonly long, which is why many people with a stable but complex history look at regulated private providers instead.
If you are weighing up the private route, the treatment options overview gives a clear sense of what's available. On cost, it's worth knowing that legitimate private semaglutide prescriptions include clinical assessment, prescriber oversight and a genuine supply chain, and that for a prescription medicine with this level of gut involvement, clinical oversight is not optional padding. It is the thing that keeps the treatment safe. Patients who also take metformin for type 2 diabetes often ask whether metformin and semaglutide can be used together, and separately, those on diabetes medicines more broadly sometimes wonder whether a drug like Farxiga is actually a form of semaglutide, both of which are worth clarifying before you start. People also occasionally ask whether semaglutide can be made or sourced outside of licensed channels, which is an important question to understand before you begin. If you take aspirin regularly, it is also worth reading about whether aspirin and semaglutide can be used alongside each other, given that many people with inflammatory conditions use both. Our frequently asked questions cover how the process works in more detail if you want to understand what to expect before starting.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.